IL138855A0 - New treatments for nervous disorders - Google Patents

New treatments for nervous disorders

Info

Publication number
IL138855A0
IL138855A0 IL13885599A IL13885599A IL138855A0 IL 138855 A0 IL138855 A0 IL 138855A0 IL 13885599 A IL13885599 A IL 13885599A IL 13885599 A IL13885599 A IL 13885599A IL 138855 A0 IL138855 A0 IL 138855A0
Authority
IL
Israel
Prior art keywords
disorders
addiction
new treatments
nervous disorders
reboxetine
Prior art date
Application number
IL13885599A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL138855A0 publication Critical patent/IL138855A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL13885599A 1998-04-09 1999-04-02 New treatments for nervous disorders IL138855A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123198P 1998-04-09 1998-04-09
PCT/US1999/004289 WO1999052531A1 (en) 1998-04-09 1999-04-02 New treatments for nervous disorders

Publications (1)

Publication Number Publication Date
IL138855A0 true IL138855A0 (en) 2001-10-31

Family

ID=22162900

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13885599A IL138855A0 (en) 1998-04-09 1999-04-02 New treatments for nervous disorders

Country Status (24)

Country Link
US (1) US6352986B1 (hu)
EP (1) EP1069900B1 (hu)
JP (1) JP2002511414A (hu)
KR (1) KR20010034758A (hu)
CN (1) CN1301164A (hu)
AT (1) ATE301462T1 (hu)
AU (1) AU756373B2 (hu)
BR (1) BR9909478A (hu)
CA (2) CA2634698A1 (hu)
CZ (1) CZ297346B6 (hu)
DE (1) DE69926616T2 (hu)
DK (1) DK1069900T3 (hu)
EA (1) EA200001049A1 (hu)
ES (1) ES2244189T3 (hu)
HU (1) HUP0102436A3 (hu)
IL (1) IL138855A0 (hu)
NO (1) NO20005059L (hu)
NZ (1) NZ507398A (hu)
PL (1) PL193797B1 (hu)
PT (1) PT1069900E (hu)
SK (1) SK14492000A3 (hu)
TR (1) TR200002868T2 (hu)
WO (1) WO1999052531A1 (hu)
ZA (1) ZA200004454B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ATE305307T1 (de) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc Reboxetin zur behandlung von migränekopfschmerzen
EP1629843A3 (en) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Company LLC Reboxetine for treating chronic fatigue syndrome
US6683114B2 (en) * 2000-03-07 2004-01-27 Eli Lilly And Company Treatment of psoriasis
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
JP4708795B2 (ja) 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9045468B2 (en) 2010-08-17 2015-06-02 Albany Molecular Research, Inc. 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
DE3275000D1 (en) * 1981-08-07 1987-02-12 Holset Engineering Co Impeller for centrifugal compressor
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EA000856B1 (ru) * 1995-07-24 2000-06-26 Эли Лилли Энд Компани Способ лечения синдрома дефицита внимания/гиперактивности
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки

Also Published As

Publication number Publication date
EA200001049A1 (ru) 2001-04-23
NZ507398A (en) 2004-01-30
JP2002511414A (ja) 2002-04-16
CZ20003671A3 (en) 2001-06-13
EP1069900B1 (en) 2005-08-10
SK14492000A3 (sk) 2001-06-11
US6352986B1 (en) 2002-03-05
NO20005059D0 (no) 2000-10-06
DE69926616T2 (de) 2006-05-24
WO1999052531A1 (en) 1999-10-21
CA2321157A1 (en) 1999-10-21
ATE301462T1 (de) 2005-08-15
ES2244189T3 (es) 2005-12-01
NO20005059L (no) 2000-10-06
EP1069900A1 (en) 2001-01-24
HUP0102436A3 (en) 2002-01-28
TR200002868T2 (tr) 2001-01-22
CZ297346B6 (cs) 2006-11-15
BR9909478A (pt) 2000-12-19
PT1069900E (pt) 2005-10-31
CN1301164A (zh) 2001-06-27
ZA200004454B (en) 2002-04-24
AU3449499A (en) 1999-11-01
CA2634698A1 (en) 1999-10-21
PL193797B1 (pl) 2007-03-30
PL346293A1 (en) 2002-01-28
KR20010034758A (ko) 2001-04-25
AU756373B2 (en) 2003-01-09
HUP0102436A2 (hu) 2001-11-28
DE69926616D1 (de) 2005-09-15
DK1069900T3 (da) 2005-10-31

Similar Documents

Publication Publication Date Title
MY127739A (en) Use of pramipexole for the treatment of addictive disorders
TW200607510A (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
PL346293A1 (en) New treatments for nervous disorders
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
MX9800864A (es) Nuevos medicamentos y su utilizacion.
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
HRP20040944B1 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
IL147876A0 (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence-dependent patients
BR0313411A (pt) Uso de reboxetina para o tratamento de ondas de calor
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
AR030364A1 (es) Compuestos para el tratamiento de desordenes adictivos
NO20005131L (no) Nye behandlinger for nervøse forstyrrelser
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
NZ511226A (en) Use of a nicotine receptor agonist in the treatment of obsessive compulsive disorder
BR0316192A (pt) Método e composições para o tratamento da ansiedade
CA2532330A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
RU2004109518A (ru) Способ лечения табачной зависимости
WO2001035946A3 (en) Intranasal administration of raloxifene and tamoxifen